Page last updated: 2024-11-05

thalidomide and Chronic Hepatitis C

thalidomide has been researched along with Chronic Hepatitis C in 2 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Research Excerpts

ExcerptRelevanceReference
"we started a prospective, open label trial of retreatment of very-difficult-to-treat genotype 1 chronic hepatitis C patients (CHC) patients, who had failed to respond to the (Peg-IFN/RBV), with a triple therapy consisting in these same antivirals plus thalidomide 200 mg/day (the TRITAL study)."9.15Thalidomide with peginterferon alfa-2b and ribavirin in the treatment of non-responders genotype 1 chronic hepatitis C patients: proof of concept. ( Dorantes, B; Eslam, M; Gallego-Durán, R; García-Collado, C; Grande, L; Morillo, R; Paradas, C; Pardo-Yules, B; Romero-Gómez, M, 2011)
"Thalidomide was well tolerated."5.33Thalidomide in the treatment of chronic hepatitis C unresponsive to alfa-interferon and ribavirin. ( Biasin, M; Clerici, M; Galli, M; Gatti, N; Milazzo, L; Moroni, M; Niero, F; Piacentini, L; Riva, A; Zanone Poma, B, 2006)
"we started a prospective, open label trial of retreatment of very-difficult-to-treat genotype 1 chronic hepatitis C patients (CHC) patients, who had failed to respond to the (Peg-IFN/RBV), with a triple therapy consisting in these same antivirals plus thalidomide 200 mg/day (the TRITAL study)."5.15Thalidomide with peginterferon alfa-2b and ribavirin in the treatment of non-responders genotype 1 chronic hepatitis C patients: proof of concept. ( Dorantes, B; Eslam, M; Gallego-Durán, R; García-Collado, C; Grande, L; Morillo, R; Paradas, C; Pardo-Yules, B; Romero-Gómez, M, 2011)
"Thalidomide was well tolerated."1.33Thalidomide in the treatment of chronic hepatitis C unresponsive to alfa-interferon and ribavirin. ( Biasin, M; Clerici, M; Galli, M; Gatti, N; Milazzo, L; Moroni, M; Niero, F; Piacentini, L; Riva, A; Zanone Poma, B, 2006)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Pardo-Yules, B1
Gallego-Durán, R1
Eslam, M1
García-Collado, C1
Grande, L1
Paradas, C1
Morillo, R1
Dorantes, B1
Romero-Gómez, M1
Milazzo, L1
Biasin, M1
Gatti, N1
Piacentini, L1
Niero, F1
Zanone Poma, B1
Galli, M1
Moroni, M1
Clerici, M1
Riva, A1

Trials

1 trial available for thalidomide and Chronic Hepatitis C

ArticleYear
Thalidomide with peginterferon alfa-2b and ribavirin in the treatment of non-responders genotype 1 chronic hepatitis C patients: proof of concept.
    Revista espanola de enfermedades digestivas, 2011, Volume: 103, Issue:12

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genes, Viral; Genotype; Hepacivirus; Hep

2011

Other Studies

1 other study available for thalidomide and Chronic Hepatitis C

ArticleYear
Thalidomide in the treatment of chronic hepatitis C unresponsive to alfa-interferon and ribavirin.
    The American journal of gastroenterology, 2006, Volume: 101, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Follow-Up Studies; Hepaciv

2006